Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 81

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 81
---
 debt financings, it could result in dilution to our existing
stockholders or increased fixed payment obligations and these securities may have rights senior to those of our common stock and could
contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to
incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial
condition and prospects.

32

Cash Flows

The following table summarizes
our cash flows for the periods indicated:

    Nine Months Ended September 30, 
  
    (in thousands) 
    2025  
    2024 
  
    Net cash and cash equivalents (used in) provided by: 

    Operating activities 
    $(19,638) 
    $(22,348)
  
    Investing activities 
     (899) 
     - 
  
    Financing activities 
     27,545  
     20,289 
  
    Change in cash and cash equivalents 
     7,008  
     (2,059)
  
    Impact on cash from foreign currency translation 
     (196) 
     (237)
  
    Cash and cash equivalents, beginning of period 
     20,922  
     35,848 
  
    Cash and cash equivalents, end of period 
    $27,734  
    $33,552 

Operating Activities 

Operating activities used
approximately $19.6 million of cash during the nine months ended September 30, 2025, resulting mainly from our loss of $40.7 million,
changes in our net operating assets and liabilities of $1.5 million, and gain on forgiveness of accounts payable of $0.6 million, partially
offset by an intangibles impairment expense of $16.5 million and non-cash stock-based compensation of $6.6 million. The change in our
net operating assets and liabilities was mainly due to an increase in other assets of $0.7 million, an increase in research and development
tax credit receivable of $0.5 million, an increase in other tax receivable of $0.5 million and a decrease in deferred liabilities of $0.5
million, partially offset by a decrease in accounts payable and accrued liabilities of $1.0 million. 

Operating activities used
approximately $